| Authors: |
van Ravenhorst MB; Department of Immunology and Infectious diseases, Wilhelmina Children's Hospital, University Medical Centre Utrecht, Utrecht, The Netherlands; Research Centre Linnaeus Institute, Spaarne Hospital, Hoofddorp, The Netherlands., Bijlsma MW; Academic Medical Centre, Centre of Infection and Immunity Amsterdam (CINIMA), Department of Neurology, Amsterdam, The Netherlands., van Houten MA; Research Centre Linnaeus Institute, Spaarne Hospital, Hoofddorp, The Netherlands., Struben VMD; Research Centre Linnaeus Institute, Spaarne Hospital, Hoofddorp, The Netherlands., Anderson AS; Pfizer Vaccine Research & Development, Pearl River, NY, USA., Eiden J; Pfizer Vaccine Research & Development, Pearl River, NY, USA., Hao L; Pfizer Vaccine Research & Development, Pearl River, NY, USA., Jansen KU; Pfizer Vaccine Research & Development, Pearl River, NY, USA., Jones H; Pfizer Vaccine Research & Development, Pearl River, NY, USA., Kitchin N; Pfizer Vaccine Research & Development, Maidenhead, UK., Pedneault L; Pfizer Vaccine Research & Development, Pearl River, NY, USA., Sanders EAM; Department of Immunology and Infectious diseases, Wilhelmina Children's Hospital, University Medical Centre Utrecht, Utrecht, The Netherlands., van der Ende A; Academic Medical Centre, Centre of Infection and Immunity Amsterdam (CINIMA), Department of Medical Microbiology and the Netherlands Reference Laboratory for Bacterial Meningitis, University of Amsterdam, Amsterdam, The Netherlands. Electronic address: A.vanderende@amc.uva.nl. |
